Actinogen Medical (ASX: ACW) released two important updates dated 20 October 2025: (1) accelerated recruitment has enabled early closure of pTau screening for the Phase 2b/3 XanaMIA Alzheimer’s trial; and (2) an Advance Overseas Finding (AOF) approval confirms eligibility for a further RDTI rebate of ~$1.87m, taking the total FY25 RDTI to ~$7.36m if the ATO amendment is favourably assessed.

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has taken a major strategic step by acquiring StemSmart™, a globally patented and clinically validated stem cell platform. This acquisition adds a powerful, next-generation therapeutic capability to the company’s focus on neuroimmune and inflammatory diseases.